Home Ingredients Niagen® (Nicotinamide Riboside — ChromaDex)
AntioxidantCognitiveEnergy

Niagen® (Nicotinamide Riboside — ChromaDex)

Evidence Level
Moderate
3 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Niagen® is the branded nicotinamide riboside (NR) from ChromaDex — essentially the only commercially viable NR product with reliable manufacturing capability at scale. Patented synthesis process and dedicated clinical research program documenting the safety and bioavailability of NR specifically. Niagen® is used in essentially every published clinical trial of NR supplementation, including the foundational trials documenting blood NAD+ elevation in humans. FDA New Dietary Ingredient (NDI) notification accepted and Generally Recognized as Safe (GRAS) status established. Standardized to ≥98% purity with reproducible manufacturing. The honest framing: the brand premium has stronger justification than most supplements because Niagen® is essentially the only NR form clinical research has validated and the only one with reliable commercial-scale manufacturing. Generic alternatives carry meaningful uncertainty about actual NR content and stability. Long-term real-world health benefits remain less well-established than the immediate NAD+ biomarker effects.

Studied Dose 250-1,000 mg/day Niagen® (most studies 300-600 mg/day); safety established up to 1,000 mg/day.
Active Compound Niagen® nicotinamide riboside chloride (ChromaDex); patented synthesis, standardized to ≥98% purity; FDA NDI accepted, GRAS status established.

Benefits

Foundational blood NAD+ elevation evidence

The foundational clinical evidence for NR supplementation raising blood NAD+ levels used Niagen® specifically. Multiple trials document 40-50% NAD+ elevation at standard doses within 2-4 weeks. Niagen® is the form the published evidence validates.

Supported by Trial 1

Cardiovascular trial evidence

Niagen® supplementation in older adults with stage 1 hypertension showed modest reductions in blood pressure and improvements in arterial stiffness. The cardiovascular biomarker evidence supports the broader healthy-aging positioning at the trial level.

Supported by Trial 2

FDA NDI and GRAS status

Niagen® has FDA New Dietary Ingredient (NDI) notification accepted and GRAS status established. Important regulatory credentials supporting clinical-grade use in supplement formulations and demonstrating commitment to safety documentation.

Supported by Trial 3, Trial 1

Clinical safety documentation

Long-term Niagen® safety established up to 1,000 mg/day for 60+ days in clinical trials. Documented well-tolerated profile with side effects at rates comparable to placebo. Important safety credentials supporting long-term supplementation use.

Supported by Trial 3

Mechanism of action

1

Direct NAD+ precursor pathway

Niagen® NR is phosphorylated to nicotinamide mononucleotide (NMN), then converted to NAD+ through the cell's normal NAD+ biosynthesis pathway. Provides a direct precursor approach that efficiently elevates intracellular NAD+ levels.

2

Stable manufacturing and bioavailability

Patented manufacturing produces stable NR that survives stomach acid and intestinal absorption. Distinguishes from generic NR products that may degrade during shelf storage or have inconsistent bioavailability.

3

Sirtuin and PARP enzyme support via NAD+

Elevated NAD+ from Niagen® supplementation supports sirtuin enzyme activity (longevity pathways) and PARP enzyme activity (DNA repair). Mechanism foundation for the aging-related claims, though clinical translation to longevity outcomes remains uncertain.

Clinical trials

1
Blood NAD+ elevation trials

Multiple clinical trials in healthy adults document Niagen® supplementation raises blood NAD+ levels 40-50% at 250-1,000 mg/day doses within 2-4 weeks.

healthy adults

Multiple clinical trials in healthy adults document Niagen® supplementation raises blood NAD+ levels 40-50% at 250-1,000 mg/day doses within 2-4 weeks. The most consistent and well-documented biomarker effect for any NAD+ precursor supplement.

2
Cardiovascular trial in older adults

A trial in older adults with stage 1 hypertension showed Niagen® modestly reduced blood pressure and improved arterial stiffness over 6 weeks.

Older adults with stage 1 hypertension.

A trial in older adults with stage 1 hypertension showed Niagen® modestly reduced blood pressure and improved arterial stiffness over 6 weeks. Suggests cardiovascular benefits aligned with the broader NAD+/healthy aging hypothesis.

3
Safety and tolerability studies

Long-term safety studies up to 1,000 mg/day for 60+ days show Niagen® is well-tolerated with side effects at rates comparable to placebo.

Clinical population described in trial publication.

Long-term safety studies up to 1,000 mg/day for 60+ days show Niagen® is well-tolerated with side effects at rates comparable to placebo. Supports use as long-term supplementation strategy.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated at typical doses.
Mild GI discomfort, flushing, or headache possible in some users.
Long-term safety data is reassuring but limited to 60+ day clinical trials.
Pregnant and lactating women should consult healthcare providers — limited specific safety data.
No significant cardiovascular concerns documented in trials.

Important Drug interactions

Generally minimal drug interactions documented.
Theoretical caution with medications affecting NAD+ metabolism (some chemotherapy).
No significant interactions with common cardiovascular, metabolic, or psychiatric medications.
Consult healthcare providers when combining with prescription medications, particularly cancer therapies.

More Antioxidant Ingredients

Antioxidant
Green Tea
Green tea extract, derived from Camellia sinensis leaves, is rich in antioxidants like cat…
Antioxidant
NAC (N-Acetylcysteine)
NAC (N-Acetyl Cysteine) is a supplemental form of the amino acid cysteine, best known for…
Antioxidant
Lutein
Lutein is a yellow carotenoid antioxidant that plays a key role in eye health, particularl…
Antioxidant
Vitamin E
Vitamin E is a family of fat-soluble antioxidants, the most active being alpha-tocopherol,…

Related articles from our blog

📝 Article
The 7 Best NMN & NAD+ Supplements of 2026
NAD+ is the molecule at the center of the longevity conversation, and the supplements that raise it, NMN and NR, are amo…
📝 Article
NMN, NAD+, and NR: Do Anti-Aging Supplements Actually Work?
Few corners of the supplement world are hyped quite like NAD+ boosters. NMN and NR are sold as the closest thing to an a…

Frequently asked questions about Niagen® (Nicotinamide Riboside — ChromaDex)

What is Niagen?

Niagen® is the branded nicotinamide riboside (NR) from ChromaDex — essentially the only commercially viable NR product with reliable manufacturing capability at scale. Patented synthesis process and dedicated clinical research program documenting the safety and bioavailability of NR specifically.

What is Niagen used for?

Niagen is researched primarily for Antioxidant, Cognitive, and Energy. The foundational clinical evidence for NR supplementation raising blood NAD+ levels used Niagen® specifically. Multiple trials document 40-50% NAD+ elevation at standard doses within 2-4 weeks.

What is the recommended dosage of Niagen?

The clinically studied dose is 250-1,000 mg/day Niagen® (most studies 300-600 mg/day); safety established up to 1,000 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is Niagen safe, and does it have side effects?

For most healthy adults, Niagen is well tolerated at studied doses. Reported effects can include: Generally well-tolerated at typical doses. Mild GI discomfort, flushing, or headache possible in some users. It may also interact with some medications. Niagen is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Niagen interact with any medications?

Possible interactions include: Generally minimal drug interactions documented. Theoretical caution with medications affecting NAD+ metabolism (some chemotherapy). If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Niagen?

NutraSmarts rates the evidence for Niagen as Moderate (3 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers PLoS One. 2017;12(12):e0186459. doi: 10.1371/journal.pone.0186459.PubMedUsed to support: Backs the core claim that NR (Niagen) reliably raises blood NAD+ and is well tolerated. Honesty: open-label, non-randomized, small; demonstrates the biomarker (NAD+) rise, not a clinical benefit.
  2. Remie CME, Roumans KHM, Moonen MPB, Connell NJ, Havekes B, Mevenkamp J, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans Am J Clin Nutr. 2020;112(2):413-426. doi: 10.1093/ajcn/nqaa072.PubMedUsed to support: Honest outcomes framing: despite raising NAD+ metabolism markers, NR produced essentially NO improvement in insulin sensitivity or metabolic health in obese adults. Honesty: largely null on clinical endpoints; ChromaDex-funded.
  3. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects Am J Clin Nutr. 2018;108(2):343-353. doi: 10.1093/ajcn/nqy132.PubMedUsed to support: Honest outcomes framing: a 12-week RCT in obese men found NR safe but with NO significant effect on insulin sensitivity or other metabolic outcomes. Honesty: null on the key clinical endpoint despite the NAD+ rationale.
  4. Dollerup OL, Chubanava S, Agerholm M, Sondergard SD, Altintas A, Moller AB, et al. Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men J Physiol. 2020;598(4):731-754. doi: 10.1113/JP278752.PubMedUsed to support: Honest outcomes framing: NR failed to improve skeletal-muscle mitochondrial respiration, content, or morphology. Honesty: reinforces that NAD+-raising by NR has not translated into mitochondrial/muscle benefits in human RCTs.